Glucagon‐like peptide‐1 receptor agonists (GLP‐1 RAs) have revolutionized obesity care, thanks to their ability to achieve clinically meaningful WL (15%–20%) after 1–1.5 years of therapy,9 emerging as a cornerstone therapy for the management of obesity and T2D. Here, GLP1R is linked to obesity due to melanocortin 4 receptor deficiency.